iNovacia develops its compound collection
- 1. iNovacia Press release Stockholm 2011-06-28 iNovacia Further Develops its Compound Collection iNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its small-molecule screening collection. This is in line with the continuous development to maintain a world leading library offered to its international pharma and biotech clients. The new and novel compounds have been developed in an exclusive joint effort together with Asinex Ltd in Moscow. Before the addition the iNovacia screening collection consisted of approximately 280,000 compounds selected based on diversity, novelty and lead-likenesses. ¡°Our screening collection is now reaching 300,000 compounds. The size and the chemical diversity of the library is well adapted for vigorous screening to develop new drug candidates. The key is to combine diversity and novelty with compounds of high purity and which are amenable for rapid optimization¡± says Dr. Martin Norin, Chief Operating Officer at iNovacia. He continues: ¡°Our chemists continuously synthesize novel scaffolds to enrich our collection even further. Typically, we have about 50-100 compounds per scaffold in our library and we have an excellent track-record in delivering viable hit and lead series to our clients¡±. Earlier this year, iNovacia introduced new filters identifying e.g. Pan Assay Interference Compounds (PAINS), promiscuous compounds that may appear as frequent false positive hits in screening campaigns, and the replacement of such compounds in the collection. This is also in line with iNovacia¡¯s strategy to maintain a screening collection of the very highest quality. About iNovacia iNovacia provides high-throughput screening, fragment-based screening and other drug discovery services to translate targets into validated leads for pharmaceutical and biotech companies. Enabled by a chemical library of highest international standard, unique biophysical tools for characterization of mode-of-action and SAR, iNovacia can minimize the technical risk and optimize lead-time and quality of drug discovery projects. iNovacia is a wholly owned subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN). About Kancera AB (publ) Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with drug candidate. Kancera is currently running two projects, one to develop a treatment leukemia and one project targeting cancer¡¯s ability to generate energy in order to survive. Kancera also develops novel cancer models that provide clinically relevant information on drug candidates before clinical trials are started. Kancera¡¯s operations are run at Pharmacia¡¯s former premises at Kungsholmen in Stockholm, Sweden. Kancera employs 20 people. The share is traded at NASDAQ OMX First North. The number of shareholders is approximately 1200. Remium AB is the Certified Advisor to Kancera. For further information, please contact: Thomas Olin, CEO +46 735 20 40 01 or thomas.olin@inovacia.se iNovacia AB Lindhagensgatan 133 SE 112 51 Stockholm www.inovacia.se